Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pfizer has reported positive data from a clinical study which showed that Lipitor 80mg demonstrated unexpected potent reduction in myocardial ischemia in patients with chronic stable angina.
Subscribe to our email newsletter
The study (DUAAL study) was a randomized, double-blind, multi-country study comparing Lipitor (n=103), Norvasc (amlodipine besylate) (n=104) and a combination of the two (n=104) in patients with coronary artery disease and chronic stable angina.
Lipitor significantly reduced the average number of ischemic events by nearly 70% and total duration of events by more than 60% from baseline to week 18 of the study, and sustained these effects until the end of the trial at week 26. In 60% of the patients treated with Lipitor, all ischemic events were completely eliminated by the end of the study. This resulted in a substantial decrease in angina attacks and need for nitroglycerin treatment.
John Deanfield, lead investigator of the Double-Blind Atorvastatin Amlodipine study, said: “Ischemia is a serious condition in which the collective effect of minor untreated events can lead to a weakening of the heart muscle and the death of heart cells. These findings were a pleasant surprise because statins are not part of the current standard of care for the treatment of angina.”